Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
AstraZeneca will have enough of its own candidate vaccine for 200 million doses by the end of 2020, with drug substance for 700 million doses by the end of the first quarter of 2021 worldwide, operations executive Pam Cheng said on Monday.
Cheng told a briefing that the company would keep the”active” drug substance in stock while it awaited regulatory approval around the world.
She said that there would be enough vaccine for 20 million doses in Britain by the end of the year, with enough”active” drug substance for 70 million doses to the UK at the end of Q1 2021.
She said she expected that to translate into 4 million finished vaccine doses by the end of 2020, and 40 million finished doses by the end of Q1 next year.
These calculations were based on using two full doses, she said, though trial data indicates higher efficacy once the initial shot is a half dose.
“If we go with a half dose you can imagine for the initial dose, we will be able to double the number of vaccinations here,” she said. She said the figures called the vaccine doses being manufactured by AstraZeneca, rather than those being made by manufacturing partners.
